QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 发表日期：2021     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naive Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study 期刊论文 BLOOD, 2021, 卷号: 138 作者:  Shi, Yuankai;  Zhang, Qing Yuan;  Hong, Xiaonan;  Wang, Zhen;  Gao, Yuhuan 收藏  |  浏览/下载：14/0  |  提交时间：2022/12/23 DAGM: A novel modelling framework to assess the risk of HER2-negative breast cancer based on germline rare coding mutations 期刊论文 EBIOMEDICINE, 2021, 卷号: 69, 页码: 11 作者:  Yang, Mei;  Fan, Yanhui;  Wu, Zhi-Yong;  Gu, Jin;  Feng, Zhendong 收藏  |  浏览/下载：44/0  |  提交时间：2021/12/01 HER2-negative breast cancer  Germline rare coding mutations  Damage assessment of genomic mutations (DAGM)  Risk assessment  Activity profiles of signalling pathways (APSP)  HER2 signalling pathway  Immune suppression   Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics. 期刊论文 JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39 作者:  Chi, Yihebali;  Gao, Ming;  Zhang, Yuan;  Shi, Feng;  Cheng, Ying 收藏  |  浏览/下载：19/0  |  提交时间：2022/01/10 Rare variants in the germline genome holistically determine receptor-independent Her2 signaling pathway activation and immune suppression, shaping pathological type and risk of HER2-negative breast cancer 期刊论文 CANCER RESEARCH, 2021, 卷号: 81, 期号: 4, 页码: 1 作者:  Yang, Mei;  Fan, Yanhui;  Wu, Zhi-Yong;  Feng, Zhendong;  Zhang, Qiangzu 收藏  |  浏览/下载：48/0  |  提交时间：2021/12/01